The Ca²⁺ sensor STIM1 regulates type I interferon response by retaining the signaling adaptor STING at the endoplasmic reticulum by Srikanth, S et al.
This is a repository copy of The Ca²  sensor STIM1 regulates type I interferon response ⁺
by retaining the signaling adaptor STING at the endoplasmic reticulum.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/140349/
Version: Accepted Version
Article:
Srikanth, S, Woo, JS, Wu, B et al. (14 more authors) (2019) The Ca²  sensor STIM1 ⁺
regulates type I interferon response by retaining the signaling adaptor STING at the 
endoplasmic reticulum. Nature Immunology. pp. 152-162. ISSN 1529-2908 
https://doi.org/10.1038/s41590-018-0287-8
© The Author(s), under exclusive licence to Springer Nature Limited 2019. This is a 
post-peer-review, pre-copyedit version of an article published in Nature Immunology. The 
final authenticated version is available online at: 
https://doi.org/10.1038/s41590-018-0287-8.
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
1 
 
The Ca2+ sensor STIM1 regulates type I interferon response by retaining 1 
the signaling adaptor STING at the endoplasmic reticulum 2 
Sonal Srikanth1, 14, 15, *, Jin Seok Woo1, 14, Beibei Wu1, Yasser M. El-Sherbiny2, 3, 4, Jennifer 3 
Leung1, Koollawat Chupradit5, 6, 7, Laura Rice8, Gil Ju Seo9, Guillaume Calmettes10, Chandran 4 
Ramakrishna11, Edouard Cantin11, Dong Sung An5, 6, 7, Ren Sun12, Ting-Ting Wu12, Jae U. Jung9, 5 
Sinisa Savic2, 13, and Yousang Gwack1, 15 * 6 
1 
Department of Physiology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA 7 
2 
National Institute for Health Research—Leeds Biomedical Research Centre and Leeds Institute of Rheumatic 8 
and Musculoskeletal Medicine (LIRMM), Wellcome Trust Brenner Building, St James’s University Hospital, 9 
Beckett Street, Leeds, UK  10 
3 
Clinical Pathology Department, Faculty of Medicine, Mansoura University, Egypt. 11 
4
 School of Science and Technology, Department of Biosciences, Nottingham Trent University, Nottingham, UK 12 
5 
Division of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA 13 
6
 School of Nursing, University of California at Los Angeles, Los Angeles, CA 90095, USA 14 
7
 UCLA AIDS Institute, Los Angeles, CA 90095, USA 15 
8
 Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Wellcome Trust Brenner Building, St 16 
James’s University Hospital, Beckett Street, Leeds, UK
 
17 
9 
Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern 18 
California, Los Angeles, CA 90033, USA 19 
10
 Department of Medicine (Cardiology), David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, 20 
USA 21 
11  
Department of Molecular Immunology, City of Hope Beckman Research Institute, Duarte, CA 91010, USA 22 
12 
Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA 90095, USA 23 
13
 Department of Clinical Immunology and Allergy, St James’s University Hospital, Leeds, UK 24 
14
 Equal contribution  25 
15 
Senior author 26 
* Corresponding author 27 
 28 
Address correspondence to: Dr. Sonal Srikanth or Dr. Yousang Gwack 29 
Department of Physiology 30 
David Geffen School of Medicine at UCLA 31 
53-266 CHS, 10833 Le Conte Avenue 32 
Los Angeles, CA 90095 33 
Tel: 310-794-2003; FAX: 310-206-5661 34 
email: ssrikanth@mednet.ucla.edu; ygwack@mednet.ucla.edu 35 
36 
2 
 
STING is an endoplasmic reticulum (ER) signaling adaptor that is essential for the type I 37 
Interferon response to DNA pathogens. Aberrant activation of STING is linked to the pathology 38 
of autoimmune and autoinflammatory diseases. The rate-limiting step for the activation of 39 
STING is its translocation from the ER to the ERÐGolgi intermediate compartment. Here we 40 
found that deficiency in the Ca2+ sensor STIM1 caused spontaneous activation of STING and 41 
enhanced expression of type I interferons under resting conditions in mice and a patient 42 
suffering from combined immunodeficiency. Mechanistically, STIM1 associated with STING to 43 
retain it in the ER membrane, and co-expression of full-length or a STING-interacting fragment 44 
of STIM1 suppressed the function of dominant STING mutants that cause autoinflammatory 45 
diseases. Furthermore, deficiency in STIM1 strongly enhanced the expression of type I 46 
interferons after viral infection and prevented the lethality of infection with a DNA virus in vivo. 47 
This work delineates a STIM1ÐSTING circuit that maintains the resting state of the STING 48 
pathway.  49 
 50 
The endoplasmic reticulum (ER) provides a structural platform for activation of the type I interferon 51 
(IFN) response. Stimulator of interferon genes (STING), a key signaling adaptor protein for DNA-52 
sensing pathways localizes to the ER membrane in the resting state1, 2, 3. After activation by cytosolic 53 
DNAs, it translocates into the ER-Golgi intermediate compartment (ERGIC) to recruit TANK-binding 54 
kinase 1 (TBK1) and interferon regulatory factor 3 (IRF3). IRF3, upon phosphorylation by TBK1, 55 
homo-dimerizes and translocates into the nucleus to induce transcription of type I IFNs4, 5, 6, 7. Beside 56 
an essential role in protecting the host against DNA pathogens, STING is also involved in the 57 
pathogenesis of autoinflammation caused by self-DNAs in murine models8, 9. Accordingly, STING has 58 
been implicated in the pathogenesis of Aicardi–Goutieres syndrome (AGS), systemic lupus 59 
erythematosus (SLE) and other type I Interferonopathies10. Furthermore, mutations in STING have 60 
been uncovered in patients with STING-associated vasculopathy with onset in infancy (SAVI) and 61 
lupus-like symptoms11, 12, 13. The STING variants found in SAVI patients are constitutively active and 62 
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localize to the ERGIC without the STING ligand, cyclic dinucleotides (CDNs), suggesting that they 63 
may escape a mechanism that potentially maintains the ER localization of STING14. Since CDNs can 64 
be generated by cytosolic self-DNAs derived from mitochondrial damage or genomic instability, and 65 
the binding affinity of STING for CDNs is high (∼5 nM for 2’,3’ cyclic guanosine monophosphate-66 
adenosine monophosphate [2’,3’-cGAMP])15, active inhibitory mechanisms are necessary to tightly 67 
control its activation. However, little is known about how the resting state of STING is maintained. 68 
High Ca2+ concentration in the ER ([Ca2+]ER) is essential for its normal function. At the same 69 
time, diverse receptors elevate cytoplasmic [Ca2+] by depleting ER Ca2+ stores through a mechanism 70 
called store-operated Ca2+ entry (SOCE). Stromal interaction molecule 1 (STIM1), an EF-hand-71 
containing Ca2+-binding protein localizes throughout the ER when [Ca2+]ER is high, but after depletion 72 
of the ER Ca2+ stores, it translocates into junctional areas between the ER and plasma membrane, 73 
interacts with the pore subunit of store-operated Ca2+ (SOC) channels; Orai1, and induces Ca2+ 74 
entry16. The essential role of STIM1 in effector function of adaptive immune cells including T and B 75 
cells has been well established17, 18, 19. Mutations in STIM1 cause severe combined immune deficiency 76 
(SCID) in humans20. Paradoxically, these patients also suffer from lymphoproliferative and 77 
autoimmune complications. Although for some forms of SCID, the mechanisms behind these 78 
complications have been worked out; for example, poor development of both central and peripheral 79 
tolerance21, the underlying causes of inflammatory complications in patients harboring mutations in 80 
STIM1 are not unknown.   81 
The role of STIM1 in cells of the innate immune system is currently unclear. Here, we 82 
examined the phenotypes of STIM1-deficient cells and observed that loss of STIM1 induces 83 
spontaneous activation of the STING-TBK1-IRF3 pathway to activate type I IFN responses under 84 
sterile conditions in both murine and human cells. Mechanistically, STIM1 directly interacted with 85 
STING to retain it in an inactive state on the ER membrane. Accordingly, we also observed strong 86 
resistance to viral infections in STIM1 KO cells and animals. These results suggest that STIM1 plays 87 
4 
 
an important role in regulation of the innate immune responses in addition to its well-established 88 
function in regulation of SOCE in adaptive immunity. 89 
Results 90 
STIM1 deficiency induces type I IFN response 91 
To gain insights into possible role of STIM1 in innate immune responses, we checked expression of 92 
various inflammatory cytokines in Stim1–/– murine embryonic fibroblasts (MEFs). Among these, 93 
transcripts of Ifnb1 and Il6 as well as interferon-stimulated genes (ISGs) were significantly increased 94 
in Stim1–/– MEFs compared to those in wild type (WT) cells (Fig. 1a). Accordingly, we observed 95 
increased amounts of secreted IFN-β protein in culture supernatants from Stim1–/– MEFs (Fig. 1b).  96 
Due to the well-established role of STIM1 in SOCE, it was possible that the increased type I IFN 97 
response in Stim1–/– MEFs was due to altered intracellular Ca2+ homeostasis. To check this possibility, 98 
we compared responses between Stim1Ð/Ð and Orai1–/– MEFs, both of which show loss of SOCE (Fig. 99 
1c). However, we did not observe enhanced Ifnb1 expression in Orai1–/– MEFs, indicating that block of 100 
SOCE or altered intracellular Ca2+ levels do not contribute to increased type I IFN response observed 101 
in Stim1–/– MEFs.  102 
To verify these observations in primary cells, we examined bone marrow-derived 103 
macrophages (BMDMs) from WT (Stim1fl/fl) and Stim1fl/flUBC-ERT2-cre mice to induce acute loss of 104 
STIM1 expression after tamoxifen treatment (Fig. 1d). Similar to MEFs, we observed enhanced 105 
expression of Ifnb1 and Il6 transcripts in Stim1Ð/Ð BMDMs. Next, we examined if this enhanced type I 106 
IFN expression phenotype was conserved in human macrophages. We generated STIM1–/– THP1 107 
cells by CRISPR/Cas9-mediated genome editing using two different gRNA sequences 108 
(Supplementary Fig. 1). Similar to murine cells, we observed an induction of IFNB1 and IL6 mRNAs 109 
and increased IFN-β secretion in STIM1–/– THP1 clones (Fig. 1e, f). Moreover, exogenous expression 110 
of STIM1 in these THP1 clones significantly rescued the phenotype by decreasing type I IFN 111 
expression. Taken together, these data strongly demonstrate an inhibitory role of STIM1 in type I IFN 112 
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responses. STIM2 is another member of the STIM family that shares 66% amino acid sequence 113 
similarity with STIM116. Both of them are ER-resident proteins, but they function differently in sensing 114 
depletion of the ER Ca2+ stores and efficacy to activate Orai channels. STIM1 plays a dominant role in 115 
activation of SOCE while STIM2 is involved in ER Ca2+ homeostasis by sensing subtle changes in 116 
[Ca2+]ER
22 23. To check a possible function of STIM2 in regulation of type I IFN responses, we 117 
generated two independent STIM2–/– THP1 clones. However, neither of the STIM2 KO clones showed 118 
elevated expression of IFNB1 transcripts (Supplementary Fig. 2). Collectively, these results establish 119 
a specific role for STIM1 in regulating the resting state of the type I IFN responses in murine and 120 
human cells.  121 
 122 
STING-TBK1-IRF3 pathway links perturbation in STIM1 expression to IFN-β expression 123 
Since both STIM1 and STING, an important regulator for the type I IFN responses, localize to the ER 124 
membrane, we checked the possibility that STIM1 regulates the function of STING. Upon activation of 125 
STING via exposure to its ligand 2’,3’-cGAMP, we observed a pronounced enhancement of Ifnb1 126 
transcript and protein levels in Stim1–/–, but not Orai1–/– MEFs when compared to those in WT MEFs 127 
(Fig. 2a). This higher type I IFN response in Stim1–/– MEFs was also observed in the presence of 128 
cytosolic DNAs after transfection with IFN stimulatory DNA (ISD) or poly(dA:dT) that are known to 129 
activate the STING pathway, but not with poly(I:C), a poor agonist of the STING pathway (Fig. 2b, 130 
left). Similarly, we observed elevated transcripts of IFNB1 in STIM1–/– THP1 cells transfected with 131 
2’,3’-cGAMP, but not poly(I:C) (Fig. 2b, right).   132 
To determine whether deficiency of STIM1 induces an increase in type I IFN response through 133 
the STING-TBK1-IRF3 pathway, we checked for activated IRF3 and TBK1 in WT and Stim1–/– MEFs. 134 
We examined localization of GFP-IRF3, which was exclusively in the cytoplasm in WT MEFs but 135 
showed almost equal distribution in the cytoplasm and nuclei in Stim1–/– MEFs (Fig. 2c). 136 
Biochemically, we detected enhanced homo-dimers of IRF3, in Stim1–/– MEFs compared to WT cells 137 
under resting conditions (Fig. 2d). Furthermore, we found enhanced levels of phosphorylated TBK1 138 
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and accordingly increased ratio of p-TBK1 vs. total TBK1 in Stim1–/– MEFs, BMDMs and STIM1–/– 139 
THP1 cells (Fig. 2e). We could also detect enhanced dimerization of endogenous STING in Stim1–/– 140 
MEFs, which is considered an active form of STING (Supplementary Fig. 3a). Likewise, STIM1–/– 141 
HEK293T cells stably expressing STING also showed enhanced STING dimers and multimers 142 
(Supplementary Fig. 3b). Next, we examined whether co-deletion of STING in STIM1-deficient cells 143 
could rescue this enhanced IFN-β expression phenotype. Deletion of both Stim1 and Tmem173 (gene 144 
encoding STING) in MEFs (double knockout, DKO) dramatically reduced Ifnb1 and Il6 transcripts 145 
under resting or cGAMP-treated conditions (Fig. 2f). Co-deletion of Tmem173 also rescued increased 146 
IFN-β secretion observed in Stim1–/– MEFs treated with poly (dA:dT) (Fig. 2g). We observed very 147 
similar results using THP1 cells. Deletion of both STIM1 and TMEM173 in double knockout (DKO) 148 
THP1 cells was confirmed by immunoblotting and SOCE measurements (Fig. 2h). DKO THP1 cells 149 
showed reduced IFNB1 and IL6 mRNA levels, suggesting that the elevated cytokine expression in 150 
STIM1–/– THP1 cells were derived from increased STING activity. Together, these results suggest that 151 
the increase in type I IFN responses observed in STIM1-deficient cells is mediated by the STING-152 
TBK1-IRF3 pathway, and STIM1 plays a novel role in type I IFN signaling via regulating STING 153 
function.  154 
 155 
Increased type I IFN responses in patient lacking STIM1 expression 156 
Previously, patients showing SCID symptoms and bearing homozygous nonsense mutation of STIM1 157 
(E136X) were shown to lack STIM1 expression due to nonsense-mediated mRNA decay24. To mimic 158 
the phenotype of this patient, we transduced STIM1-deficient cells with viral vectors encoding WT and 159 
STIM1E136X proteins. We confirmed lack of STIM1 expression in Stim1Ð/Ð MEFs transduced to express 160 
STIM1E136X while those with STIM1WT showed expression similar to the endogenous protein in WT 161 
MEFs (Fig. 3a). Importantly, expression of STIM1WT but not STIM1E136X rescued the increased type I 162 
IFN response in Stim1–/– MEFs (Fig. 3b).  163 
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 To examine if this was true in STIM1-deficient patients, we harvested primary cells from a 164 
patient lacking STIM1 expression due to a homozygous STIM1 mutation c.478del, p.(Ser160fs). The 165 
lack of STIM1 expression in patient’s PBMCs was confirmed by immunoblotting (Fig. 3c). Patient 166 
serum showed enhanced IFN-β, IL-6 and TNF cytokines when compared to those observed in three 167 
healthy controls (Fig. 3d). Consistently, we also observed enhanced expression of ISGs in PBMCs 168 
and monocytes from the patient, when compared to those in two healthy controls (Fig. 3e). 169 
Interestingly, the patient also exhibited very mild SAVI-like symptoms – he suffered from 170 
desquamation and blistering with skin eruptions mainly affecting the palm, soles of the feet and 171 
cheeks. He also showed pronounced nail dystrophy25. Together, these data confirm that loss of 172 
STIM1 in humans enhances expression of type I IFN, proinflammatory cytokines and ISGs, similar to 173 
murine cells. 174 
 175 
STIM1 interacts with STING for its retention at the endoplasmic reticulum 176 
The increased type I IFN response together with higher basal activity of the STING-TBK1-IRF3 177 
pathway in STIM1-deficient cells suggests that STIM1 may be involved in maintaining the resting state 178 
of the STING pathway. Microscopy analysis showed a strong co-localization between STIM1 and 179 
STING in the ER (Fig. 4a). Hence, we checked if STIM1 can physically interact with STING to retain it 180 
in the ER. When co-expressed in HEK293T cells, STIM1 was specifically identified from 181 
immunoprecipitates of STING (Fig. 4b). In addition, we also validated association between 182 
endogenous STIM1 and STING proteins by immunoprecipitation (Fig. 4c). This association was 183 
specific because another ER-resident protein, calnexin could not be detected in immunoprecipitates of 184 
STIM1.   185 
Next, we examined association between STIM1 and STING upon activation of either of the 186 
proteins. We activated STIM1 by treatment with thapsigargin that depletes the ER Ca2+ stores, and 187 
activated STING using its ligand, 2’,3’-cGAMP. We observed reduced biochemical association 188 
between the two proteins by stimulation of either STIM1 or STING (Fig. 4d). These data indicate that 189 
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STING and STIM1 form a protein complex that is dissociated due to conformational changes induced 190 
by stimulation of either of these proteins. Association between STING and STIM1 prompted us to 191 
check for a possible role of STING in regulating the function of STIM1. We observed reduced SOCE 192 
induced by thapsigargin or anti-CD3 antibody treatment in HEK293T and Jurkat T cells 193 
overexpressing STING (Supplementary Fig. 4a, b, c). In addition, we observed enhanced STIM1 194 
translocation to the ER-PM junctions in thapsigargin treated STING-deficient (Tmem173–/–) MEFs 195 
(Supplementary Fig. 4d). Conversely, there was significant enhancement of SOCE in TMEM173–/– 196 
Jurkat cells (Supplementary Fig. 4e, f). This enhancement was not observed in THP1 cells, indicating 197 
cell type specificity (Fig. 2h). Taken together, these data show that association with STING impacts 198 
the function of STIM1 in mediating SOCE.  199 
STING contains four transmembrane (TM) segments in its N terminus that span the ER 200 
membrane (Fig. 4e)1. STING N-terminal domain (NTD) containing the TM segments plays an 201 
important role in its ER localization, trafficking and interaction with regulators including ZDHHC1, 202 
AMFR, TRIM32, and RNF526, 27, 28, 29. Tumor DNA viral proteins, E1A and E7 also bind to STING NTD 203 
to inhibit downstream signaling28. The cytoplasmic region (C-terminal domain, CTD) of STING 204 
contains the dimerization domain (DD), CDN-binding region, and the C-terminal tail (CTT) that 205 
interacts with TBK1 and IRF3. STIM1 has an N-terminal ER-luminal region containing the Ca2+-206 
sensing EF-hand motifs and sterile alpha motif (SAM) domain that is important for its multimerization 207 
after ER Ca2+ depletion. It also has a single TM domain that traverses the ER membrane. The 208 
cytoplasmic C terminus contains multiple functional domains including coiled-coil domains (CC) 1, 209 
CC2, CC3, a serine/threonine-rich domain (S/T), and a lysine-rich domain (poly-K) that are important 210 
for binding to the plasma membrane after depletion of ER Ca2+ stores. A fragment containing CC2 211 
and CC3 of STIM1 called the CRAC activation domain (CAD) or the STIM1 Orai activating region 212 
(SOAR) was identified to interact directly with Orai1 subunits to gate them16, 29. 213 
To determine their interaction domains, we carried out co-immunoprecipitation using lysates of 214 
HEK293T cells overexpressing full-length, NTD or CTD of STING together with full-length STIM1. 215 
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These results showed NTD of STING as a major STIM1-interacting domain while its CTD interacted 216 
weakly with STIM1 (Fig. 4f, left panels). To uncover the domain(s) of STIM1 involved in interaction 217 
with STING, we performed GST pull-down experiments by incubating bacterially purified GST-fused 218 
fragments of STIM1 with lysates of HEK293T cells overexpressing full-length, NTD or CTD of STING. 219 
From this analysis, we identified a predominant interaction between the N terminus of STIM1 220 
containing the TM segment (a.a. 1-249) and STING NTD, and a weaker binding of the cytoplasmic 221 
fragment predominantly containing the S/T-rich region of STIM1 to STING CTD (Fig. 4f, right panels). 222 
These data suggest that interaction between STIM1 and STING is predominantly mediated by their 223 
TM domains on the ER membrane with weak additional interactions between their cytoplasmic 224 
regions.  225 
 226 
STIM1 acts as an ER retention factor to suppress the activity of STING 227 
Ligand binding induces conformational rearrangement and trafficking of STING from the ER to the 228 
ERGIC and the Golgi apparatus14, 30, 31.  Since STIM1 interacted strongly with STING NTD, which is 229 
crucial for STING localization, we hypothesized that STIM1 may control the ER localization of STING. 230 
To validate this hypothesis, we examined the localization of STING in WT and Stim1–/– MEFs by co-231 
staining with ERGIC marker (ERGIC-53/p58). We observed a significant population of Stim1–/– MEFs 232 
showing partial localization of STING at the ERGIC without any stimulation, and this population 233 
increased much faster in Stim1–/– MEFs infected with the DNA virus, herpes simplex virus type-1 234 
(HSV-1) when compared to WT MEFs (Fig. 5a).  To check how interaction with STIM1 influences the 235 
function of STING, we monitored the translocation kinetics of STING after treatment of WT or Stim1–/– 236 
MEFs with 2’,3’-cGAMP and observed faster translocation of STING into the ERGIC in Stim1–/– MEFs 237 
than in WT cells (Fig. 5b). Together with our biochemical analysis, these data suggest that STIM1 238 
physically interacts with STING to promote its retention onto the ER membrane. 239 
We checked if overexpression of STIM1 can inhibit the function of STING using Ifnb promoter-240 
driven luciferase reporter (IFN-Luc) assays after 2’,3’-cGAMP treatment. In cells co-expressing STING 241 
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and increasing amounts of full length or the N- and C-terminal binding fragments of STIM1, we 242 
observed a dose-dependent inhibition of luciferase reporter expression (Fig. 5c). In support of our 243 
biochemical analyses, the N-terminal TM-containing fragment of STIM1 (a.a. 1-249) showed a 244 
stronger inhibition of luciferase reporter activity than the cytoplasmic domain (a.a. 400-600) while 245 
STIM1 fragments (a.a. 250-400 and a.a. 600-685) that do not interact with STING did not affect 246 
luciferase activity. Of note, expression of full-length STIM1 or its N-terminal fragment (a.a. 1-249) did 247 
not influence the luciferase activity when stimulated with poly(I:C). These data validate functional 248 
interaction between STIM1 and STING proteins.  249 
The genetic lesions of patients exhibiting autoinflammatory vasculopathy and autoimmunity 250 
were mapped to single amino acid substitutions in STING11. These substitution mutations changed 251 
one of the conserved residues V147, N154, or V155, all of which are localized in or around the STING 252 
dimerization domain32. In addition, these substitutions lead to localization of STING at the ERGIC and 253 
constitutive TBK1 and IRF3 activation and uncontrolled type I IFN response11, 13. We examined if 254 
these disease-associated STING mutants retained binding to STIM1. Using immunoprecipitation 255 
analysis, we observed reduced interaction of the STING SAVI mutants with STIM1 and 256 
overexpression of full-length or N-terminal fragment of STIM1 could suppress Ifnb promoter-driven 257 
luciferase activity of these mutants. (Supplementary Fig. 5a, b). In support of these data, confocal 258 
analyses showed a partial block of constitutive ERGIC localization of these mutants in the presence of 259 
STIM1 (Supplementary Fig. 5c). Collectively, these results confirm the previous observations that exit 260 
from the ER is an important step for the activation of STING and STIM1 can block this trafficking via 261 
direct interaction.  262 
 263 
Genetic inhibition of STIM1 expression primes antiviral activity 264 
We sought to determine whether deficiency of STIM1 influences activation of the type I IFNs in 265 
response to DNA virus infection. To examine this, WT and Stim1–/– MEFs were infected with DNA 266 
viruses (e.g., HSV-1 and murine γ-herpesvirus, MHV-68). Spontaneous induction of IFN-β observed in 267 
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Stim1–/– MEFs was substantially increased after HSV-1 infection (Fig. 6a). We also observed a 268 
marked reduction in expression of GFP, encoded from the viral genome which served as an indicator 269 
for viral replication in Stim1–/– MEFs. We observed similar results using another DNA virus, MHV-68. 270 
Similar to HSV-1 infection, MHV-68-infected Stim1–/– MEFs showed much lower expression of the 271 
viral genome-driven GFP, as well as early and late phase viral transcripts (e.g., ORF57 and ORF29, 272 
respectively), indicative of a lower viral burden (Fig. 6b). In consistence with these data, Stim1–/– 273 
MEFs showed enhanced phosphorylation of IRF3 upon HSV-1 infection (Fig. 6c). We observed 274 
similar results in primary cells, where Stim1–/– BMDMs showed enhanced expression of Ifnb1 and Il6 275 
mRNAs under resting conditions, as well as after HSV-1 infection (Fig. 6d). Together, these data 276 
show that loss of STIM1 increases resistance to DNA virus infections.  277 
Next, we validated these observations in STIM1–/– THP1 macrophages. Similar to data with 278 
mouse cells, STIM1 deficiency rendered human macrophages resistant to HSV-1, decreasing 279 
expression of GFP as observed by microscopy and transcript analyses (Fig. 6e). Accordingly, we 280 
observed enhanced expression of IFNB1 transcripts in STIM1–/– THP1 cells. Previously, it was shown 281 
that anti-viral immunity against HIV infection also relies on the cGAS-STING pathway due to the 282 
presence of cytosolic DNA generated by reverse-transcription8, 33. To investigate whether STIM1 283 
deletion imparts resistance to HIV, we infected wild type and STIM1–/– THP1 cells with GFP-HIV and 284 
observed a dramatic reduction of HIV infection in STIM1–/– THP1 cells as judged by frequency of 285 
GFP+ cells (Fig. 6f). Together, these results suggest that deficiency of STIM1 can prime host 286 
response against infection with DNA viruses and retroviruses in various murine and human cell types.  287 
Many DNA viruses, including HSV-1 are known to activate Ca2+ signaling for a productive 288 
infection34. Hence it is possible that resistance to DNA virus infection in Stim1–/– MEFs may be due to 289 
loss of SOCE. To determine the contribution of SOCE versus enhanced STING activity in host 290 
resistance to DNA virus infection, we compared responses of Stim1–/– and Orai1–/– MEFs to HSV-1 291 
infection. We observed a moderate resistance to HSV-1 infection in Orai1–/– MEFs, but in comparison, 292 
the resistance to HSV-1 infection was approximately 100-fold more pronounced in Stim1–/– cells 293 
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(Supplementary Fig. 6a). In support of the SOCE-independent role of STIM1 in regulation of STING 294 
function, we found that Ifnb1 mRNA expression was not increased after HSV-1 infection in Orai1–/– 295 
cells contrary to Stim1–/– cells. Finally, Stim1–/– MEFs when treated with inhibitor of the IFN receptor-296 
JAK-STAT pathway, tofacitinib, became susceptible to HSV-1 infection (Supplementary Fig. 6b). 297 
Together, these results indicate a predominant role of the type I IFN pathway in the resistance of 298 
STIM1-deficient cells to viral infections.  299 
 300 
Ablation of STIM1 primes type I IFN response in vivo 301 
To gain insight into the importance of STIM1 in host defense against viral infection in vivo, we 302 
investigated the antiviral immune response in Stim1fl/fl and Stim1fl/flLyz2-cre mice. In parallel, to 303 
compare the contribution of SOCE in host resistance to viral infections, we generated conditionally 304 
targeted Orai1 animals (Supplementary Fig. 7a), which were bred with Lyz2-cre for two generations. 305 
BMDMs differentiated from bone marrows of Orai1fl/flLyz2-cre animals showed almost a complete loss 306 
of Orai1 transcripts and SOCE (Supplementary Fig. 7b, c). Since HSV-1 is a neurotropic virus and the 307 
leading cause of sporadic viral encephalitis, we investigated the effects of Orai1 and Stim1 deficiency 308 
on HSV-1-induced lethality and viral loads in the brain. When infected with HSV-1 intravenously, 309 
control (Stim1fl/fl and Orai1fl/fl) as well as Orai1fl/flLyz2-cre animals showed susceptibility and died 310 
within 6-8 days of infection (Fig. 7a, b). In contrast Stim1fl/flLyz2-cre mice were completely resistant to 311 
HSV-1-induced lethality, and accordingly, recovered from loss of body weight. Viral titers in the brains 312 
obtained from Stim1fl/flLyz2-cre mice were significantly lower than Stim1fl/fl animals (Fig. 7c). 313 
Importantly, serum cytokine measurements showed elevated levels of serum IFN-β, IL-6 and TNF in 314 
uninfected as well as HSV-1-infected Stim1fl/flLyz2-cre mice, when compared to littermate controls 315 
(Fig. 7d). Taken together, our data indicate that genetic deletion of Stim1 but not Orai1 can impart 316 
protection from HSV-induced encephalitis and lethality, due to pre-activation of the STING-mediated 317 
type I IFN signaling pathway.  318 
 319 
13 
 
Discussion 320 
STING and STIM1 commonly contain transmembrane domain(s) in their N termini and predominantly 321 
localize to the ER membrane. Co-immunoprecipitation experiments showed an association between 322 
the two proteins, that was primarily mediated by their N-terminal transmembrane domains. We 323 
showed that loss of STIM1 renders cells and mice strongly resistant to viral infections due to 324 
enhanced expression of type I IFNs and pro-inflammatory cytokines. Importantly, a patient with a 325 
mutation in STIM1 that abrogated STIM1 expression also showed elevated cytokines and ISGs. 326 
Furthermore, some of the patient’s clinical features, principally the skin and nail manifestations 327 
resemble that of SAVI patients, suggesting that the excessive type I IFNs do have adverse biological 328 
manifestation in this condition25. Mechanistically, enhanced translocation and dimerization of STING 329 
by STIM1 deficiency suggest that STIM1 may preferentially bind to STING monomers at the ER to 330 
prevent its spontaneous activation.  Conversely, we also found that STING deficiency augmented 331 
translocation of STIM1 and Ca2+ entry triggered by depletion of ER Ca2+ stores. Therefore, our studies 332 
suggest that physical and functional association between STIM1 and STING is crucial for 333 
maintenance of the resting state of both pathways.  334 
We showed that enhanced type I IFN expression in STIM1-deficient cells is not mediated by 335 
Ca2+ signaling by comparative studies with Orai1-deficient cells and animals. STIM1 deficiency made 336 
cells and mice strongly resistant to HSV-1 infections. Since many viruses including HSV-134, require 337 
elevated Ca2+ levels for their replication, we determined the contribution of the Ca2+-dependent (i.e., 338 
decreased SOCE) vs. Ca2+-independent mechanisms (i.e., enhanced type I IFN response) involved in 339 
anti-viral immunity in STIM1-deficient cells using two independent molecular tools, Orai1Ð/Ð cells/mice 340 
and JAK inhibitors. These results suggest that decreased viral burden in STIM1-deficient cells and 341 
mice is predominantly derived from enhanced type I IFN responses. Whether the same principle can 342 
be applied to other viruses with various degrees of dependence on Ca2+ signaling and activation of 343 
the STING pathway needs further studies.  344 
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Although much is understood regarding the mechanisms underlying activation of STING 345 
including ligand binding, trafficking and interaction with downstream effector molecules, little is known 346 
about regulation of its resting state. Multiple mechanisms underlying STING inhibition have been 347 
uncovered due to the importance of timely inactivation of the type I IFN signaling pathway. NLRX1 348 
and ATG9a have been shown to inhibit STING-TBK1 interaction26, 27. In addition, K48-linked 349 
polyubiquitination by RNF5 and TRIM30a results in STING degradation after ligand binding35, 36. All 350 
these inhibitory mechanisms target STING function after ligand binding and trafficking. However, 351 
inhibition of STING trafficking by brefeldin A, an inhibitor of ADP ribosylation factor (ARF) GTPases, 352 
blocks activation of the downstream pathway, suggesting that trafficking of STING is crucial for its 353 
function14. Consistently, our studies reveal a novel mechanism of regulation of STING activity, 354 
inhibition of STING trafficking via direct interaction with STIM1. Activity of three of the disease-355 
associated STING variants; V147L, N154S, and V155M was suppressed by STIM1 in part via 356 
blocking their translocation to the ERGIC, demonstrating a therapeutic potential of our finding. In 357 
summary, our study identifies STIM1 as an “ER retention factor” to maintain ER residency and 358 
inactive conformation of STING. Further, it suggests that one of the primary functions of CDN binding 359 
to STING is to disrupt its association with STIM1 that would allow exit of STING from the ER. Further 360 
dissection of the mechanisms underlying maintenance of the resting state of STING may inform the 361 
design of specific therapeutic strategies geared towards enhancement/inhibition of STING activity in 362 
the context of vaccination and sterile inflammatory diseases (e.g., AGS and SAVI), respectively. 363 
 364 
Methods 365 
Chemicals and Antibodies. Fura 2-AM (F1221) was purchased from ThermoFisher Scientific. 366 
Thapsigargin and ionomycin were purchased from EMD Millipore. Poly(I:C) (P1530) was purchased 367 
from Millipore Sigma. Poly(dA:dT) (tlrl-patn) and 2’,3’-cGAMP (tlrl-nacga23) were purchased from 368 
InvivoGen. Tofacitinib (S500110MG) was purchased from Selleck Chemical LLC. Antibodies for 369 
detection of STIM1 (5668S), phosphor-IRF3 (29047S), IRF3 (4302S), phosphor-TBK1 (5483S), total 370 
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TBK1 (3504S), STING (13647S), 6xHis tag (12698S), and STIM2 (4917S) were purchased from Cell 371 
Signaling Technologies. Antibodies for detection of FLAG tag (F3040), p58 (ERGIC marker, E1031) 372 
and human Orai1 (AB9868) were purchased from Millipore Sigma. Antibody for detection of  β-actin 373 
(sc-47778) was obtained from Santa Cruz Biotechnology and antibodies for detection of STIM1 (clone 374 
5A2) and GAPDH (GTX100118) from human PBMCs were obtained from Sigma and GeneTex 375 
respectively.  376 
Plasmids and cells. STIM1-YFP plasmid has been described previously37. Human STIM1 cDNA was 377 
subcloned into a lentiviral vector, FGllF (kind gift from Dr. Dong Sun An, UCLA) with a C-terminal 378 
FLAG tag and pcDNA 3.1 mychis plasmid. GST-tagged truncated fragments of STIM1 corresponding 379 
to amino acids 1-249 (containing the EF-hand, SAM domain and transmembrane segment), 250–400 380 
(containing coiled-coil domains 1 and 2), the CAD domain (amino acids 342–448), 400–600 (the 381 
serine and threonine-rich region), and 600–685 (the C-terminal PIP2-interacting domain) have been 382 
previously described37. Fragments of STING corresponding to the N-terminal TM domain (a.a. 1-154) 383 
and C-terminal domain (a.a. 149-379), both tagged with a FLAG tag in the C-terminus, were 384 
subcloned into pMSCV-CITE-eGFP-PGK-Puro vector. Full-length cDNA of human STING and SAVI 385 
mutants corresponding to V147L, N154S and V155M were subcloned into pEGFPN1 vector to 386 
generate a C-terminal GFP fusion protein and into pMSCV-CITE-eGFP-PGK-Puro vector that 387 
encodes a C-terminal FLAG tag using primers described in Supplementary Table 1. Oligonucleotides 388 
encoding sgRNAs to delete STIM1, STIM2 and STING were subcloned into lentiGuide-Puro vector 389 
(Addgene, #52963). HEK293T, Vero and Jurkat E6-1 T cell lines were obtained from American Type 390 
Culture Collection center (ATCC, Manassas, VA). WT and Stim1-/- MEFs were generated by breeding 391 
Stim1fl/fl mice (Jackson Laboratory, stock No. 023350) with CMV-cre mice (Jackson Laboratory, stock 392 
No. 006054). MEFs were established using standard protocols from E14.5 embryos and retrovirally 393 
transduced with SV40 large T antigen in a plasmid encoding hygromycin resistance for 394 
immortalization. Orai1-/- MEFs have been previously described38.  395 
Cell Culture. MEFs, Vero and HEK293T cells were grown in complete DMEM (Mediatech) 396 
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supplemented with 10% (v/v) fetal bovine serum (Hyclone), 2 mM L-glutamine (Mediatech), 10 mM 397 
HEPES (Mediatech) and Penicillin/Streptomycin (Mediatech) at 37°C and 5% CO2. BMDMs were 398 
differentiated from bone marrow cells isolated from femur and tibia of 6-8-week-old mice. For 399 
preparation of BMDMs, the bone marrow cells were cultured in 10% M-CSF-containing conditional 400 
medium from HEK293T cells expressing recombinant M-CSF (a kind gift from Stephen Smale lab, 401 
UCLA) for 4-6 days. BMDMs were cultured in the absence of M-CSF for at least 24 hours prior to 402 
experimental use. THP1 and Jurkat T cells were cultured in RPMI (Mediatech) containing 10% fetal 403 
bovine serum (Hyclone). Cells were infected with indicated MOIs of indicated viruses and harvested in 404 
TRIzol Reagent for transcript expression analysis. For 2’,3’-cGAMP treatment, MEFs or HEK293T 405 
cells were treated with or without 1 µM 2’,3’-cGAMP for 30 mins in digitonin permeabilization buffer 406 
(50 mM HEPES, 100 mM KCl, 3 mM MgCl2, 0.1 mM DTT, 85 mM sucrose, 0.2% BSA, 1 mM ATP, 0.1 407 
mM GTP, pH 7.0) followed by culture medium for indicated times, after which the cells were harvested 408 
for transcript analysis or reporter assays. MEFs were transfected with 5 µg of interferon stimulatory 409 
DNA (ISD39), polydA:dT or poly I:C using Lipofectamine 2000 (Thermofisher Scientific). For ELISAs, 410 
MEFs were treated with cGAMP as described and supernatant harvested after 24 hrs.  411 
Mice. Stim1fl/fl animals were purchased from Jackson Laboratory (stock No. 023350) and bred with 412 
Lyz2-cre animals (Jackson Laboratory, stock No. 004781) for two generations. Targeting of murine 413 
Orai1 was performed by flanking exon 2 with LoxP sites by homologous recombination in AB2.2 414 
(129SvEv) embryonic stem (ES) cells. Exon 2 encodes for 201 a.a. out of a total of 304 a.a. of Orai1 415 
protein. G418-resistant clones were screened by PCR for homologous recombination at both 416 
homology arms. Chimeric mice with floxed Orai1 alleles were generated by blastocyst injection of 417 
heterozygous Orai1fl/+ ES cell clones. Founder Orai1fl/+ mice were bred with Flp-deleter mice (Jackson 418 
Laboratory) to remove the neomycin resistance gene cassette. Orai1fl/fl mice were backcrossed to 419 
C57/BL6/J mice for at least 10 generations and then bred with Lyz2-cre mice to generate myeloid-420 
specific deletion of Orai1. All mice were maintained in pathogen-free barrier facilities and used in 421 
accordance with protocols approved by the Institutional Animal Care and Use Committee at the 422 
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UCLA.  423 
Patient. Sample collection from the patient was performed after obtaining written consent from his 424 
parents according to the principles of the Declaration of Helsinki and after local ethics approval. 425 
Detailed clinical evaluation was undertaken in appropriate clinical setting. PBMC isolation from 426 
healthy control and patient human blood samples was performed by gradient separation using 427 
Lymphoprep (Stem Cell Technologies). Monocytes were purified from PBMCs using a Monocytes 428 
separation kit II (# 130-091-153, Miltenyi Biotec). The patient is a 4-year-old boy of consanguineous 429 
Pakistani background, who initially presented to paediatric neurology due to poor mobility. A diagnosis 430 
of STIM1 deficiency was made following referral to paediatric immunology due to recurrent 431 
sinopulmonary infections. The patient has typical non-immunological features consistent with STIM1 432 
deficiency including amelogenesis imperfecta resulting in complete dental clearance, anhidrosis and 433 
muscle weakness. Surprisingly, the patient had mild immunodeficiency phenotype, with relatively 434 
preserved immunological function, including appropriate responses to challenge vaccination25. 435 
Virus amplification and concentration. MHV68-GFP virus was amplified and titrated in NIH3T3 436 
cells using standard protocols. HSV-1 KOS strain was used for all in vitro experiments and HSV-1 17+ 437 
strain was used for in vivo infection experiments. Both the strains were amplified and titrated in Vero 438 
cells using standard protocols. HSV-1 17+ strain was concentrated for in vivo experiments. VSV-G 439 
pseudotyped HIV-1NL4-3 strain-GFP reporter virus was amplified and titrated in HEK293T cells using 440 
standard protocols. 441 
RNA isolation, cDNA synthesis and Real-time quantitative PCR. Total RNA from cells harvested 442 
in TRIzol Reagent (ThermoFisher) was isolated using the Direct-zol RNA isolation kit (Zymo 443 
Research). RNA quantity and quality were confirmed with a NanoDrop ND-1000 spectrophotometer. 444 
cDNA was synthesized using 2-3 µg of total RNA using oligo(dT) primers and Maxima Reverse 445 
Transcriptase (Thermofisher Scientific). Real-time quantitative PCR was performed using iTaq 446 
Universal SYBR Green Supermix (Bio-Rad) and an iCycler IQ5 system (Bio-Rad) using gene-specific 447 
primers described in Supplementary Table 1. Threshold cycles (CT) for all the candidate genes were 448 
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normalized to those for 36b4 to obtain ∆CT and further normalized to the values obtained for WT 449 
samples to obtain ∆∆CT. The specificity of primers was examined by melt-curve analysis and agarose 450 
gel electrophoresis of PCR products. Total RNA from human patient and healthy donors PBMCs and 451 
monocytes harvested was isolated using the Total RNA purification Kit (Norgen Biotek Corp.). cDNA 452 
was synthesized using 1-2 µg of total RNA using High-Capacity cDNA Reverse Transcription Kit 453 
(ThermoFisher Scientific). Real-time quantitative PCR was performed using TaqMan Universal PCR 454 
Master Mix (ThermoFisher Scientific) using FAM-MGB probes for detection of MX1 455 
(Hs00895608_m1), IFI44 (Hs00951349), IFI44L (Hs00915292_m1), IFI27 (Hs01086370_m1), ISG15 456 
(Hs00192713_m1), CXCL10 (Hs01124251_g1), RSAD2 (Hs01057264_m1), IFIT1 (Hs01675197_m1), 457 
IFI6 (Hs00242571_m1), OAS1 (Hs00973635_m1), IL6 (Hs00985639_m1), and HPRT1 458 
(Hs99999909_m1). The relative abundance of each transcript was normalized to the expression level 459 
of HPRT1 to obtain ∆CT and further normalized to the values obtained for healthy controls to obtain 460 
∆∆CT.  461 
Cytokine measurement by ELISA. ELISA was performed on cell culture supernatants from indicated 462 
cells or serum samples harvested from mock or HSV-1-infected animals for detection of IFNβ 463 
(Biolegend, # 439407), IL-6 (ThermoFisher, # 88-7064-88) and TNF (ThermoFisher, # 88-7324-88). 464 
Serum samples obtained from healthy controls or STIM1-deficient human patient were used for 465 
detection of IFNβ (PBL Assay Science, #41410), IL-6 (ThermoFisher Scientific, # 88-7066-22) and 466 
TNF (ThermoFisher Scientific, # 88-7346-22). 467 
Single-cell Ca2+ imaging, live-cell epifluorescence or TIRF microscopy and confocal 468 
microscopy. THP1 and Jurkat T cells were loaded at 1 x 106 cells/ml with 1 µM Fura 2-AM for 40 min 469 
at 25oC and attached to poly-L-lysine–coated coverslips. MEFs or BMDMs were grown overnight on 470 
coverslips and loaded with 1 µM Fura 2-AM for 40 min at 25oC for imaging. Intracellular [Ca2+]i 471 
measurements were performed using essentially the same methods as previously described40. For 472 
live-cell epifluorescence imaging of STING-GFP translocation kinetics, MEFs grown on coverslips 473 
were perfused with Ringer’s solution containing (in mM): 155 NaCl, 4.5 KCl, 2 CaCl2, 1 MgCl2, 10 D-474 
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glucose, and 5 Na-HEPES (pH 7.4) and used for time course imaging. Cells were perfused with 475 
digitonin permeabilization buffer (50 mM HEPES, 100 mM KCl, 3 mM MgCl2, 0.1 mM DTT, 85 mM 476 
sucrose, 0.2% BSA, 1 mM ATP, 0.1 mM GTP, pH 7.0) containing 1 µM 2’,3’-cGAMP for 10 mins and 477 
then the medium was replaced with Ringer’s solution. For TIRF analysis of STIM1-YFP translocation, 478 
MEFs were plated onto coverslip bottom dishes in medium and used for experiments. Medium was 479 
replaced with Ringer’s solution and cells were treated with 1 µM thapsigargin for passive depletion of 480 
ER Ca2+ stores to monitor STIM1 translocation. TIRF microscopy was performed using an Olympus 481 
IX2 illumination system mounted on an Olympus IX51 inverted microscope using previously described 482 
methods37. Acquisition and image analysis were performed using Slidebook (Intelligent Imaging 483 
Innovations, Inc.) software and graphs were plotted using OriginPro8.5 (Originlab). For quantification 484 
of TIRF intensity across different cells, individual regions of interest were selected and data were 485 
analyzed as the ratio of fluorescence intensity at each time-point (F) to that at the start of the 486 
experiment (F0). For confocal analysis, uninfected or HSV-infected MEFs were fixed for 20 mins with 487 
2.5% PFA at room temperature, permeabilized in buffer containing PBS + 0.2% Triton X-100, blocked 488 
with same buffer containing 1% BSA and used for staining of ERGIC marker and confocal analysis. 489 
Confocal laser scanning microscopy was performed using Fluoview FV10i Confocal Microscope 490 
(Olympus), images were captured with a 60x oil objective. Images were processed for enhancement 491 
of brightness or contrast using Fluoview software. 492 
Generation of STIM1, STIM2 and STING-deficient cells using CRISPR-Cas9 system. To generate 493 
lentiviruses for transduction, HEK293T cells were transfected with plasmid(s) encoding sgRNA and 494 
packaging vectors (pMD2.G and psPAX2, Addgene) using calcium phosphate transfection method. 495 
Lentiviruses encoding Cas9 were generated using the same technique. Culture supernatants were 496 
harvested at 48 and 72 hours post transfection and used for infection (50% of Cas9-encoding virus + 497 
50% of sgRNA-encoding virus) of MEFs, THP1 or Jurkat T cells together with polybrene (8 µg/ml) 498 
using the spin-infection method. Cells were selected with puromycin (1 µg/ml) and blasticidin (5 µg/ml) 499 
48 hours post infection. The sequences of the sgRNAs are described in Supplementary Table 1. 500 
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Immunoprecipitation and immunoblotting. For immunoprecipitation, cDNA encoding full-length or 501 
fragments (a.a. 1-154 and 149-379) of FLAG-tagged STING and 6xHis-tagged STIM1 was transfected 502 
into HEK293T cells. Transfected cells (2 x 107) were lysed in lysis buffer (20 mM Tris-Cl, 2 mM EDTA, 503 
135 mM NaCl, 10% (vol/vol) glycerol, 0.5% Igepal CA-630, protease inhibitor mixture, pH 7.5) and 504 
centrifuged at 100,000 x g for 1 hour before preclearing with protein G-Sepharose. Lysates were 505 
immunoprecipitated with anti-FLAG antibody-conjugated resin for 6 hours. Immunoprecipitates were 506 
washed five times in lysis buffer and analyzed by immunoblotting. For immunoblot analyses, cells 507 
were lysed in RIPA buffer (10 mM Tris-Cl, 1% Triton X-100, 0.1% SDS, 140 mM NaCl, 1 mM EDTA, 508 
0.1% sodium deoxycholate, and cOmplete Protease Inhibitor Cocktail [Sigma-Aldrich], pH 8.0) and 509 
centrifuged to remove debris. Samples were separated on 8-10% SDS-PAGE. Proteins were 510 
transferred to nitrocellulose membranes and subsequently analyzed by immunoblotting with relevant 511 
antibodies. For dithiobis succinimidyl propionate (DSP) crosslinking, MEFs or HEK293T cells were left 512 
untreated or treated with 0.125, 0.25, 0.5, or 1.0 mM of DSP for 1 hour on ice, followed by quenching 513 
with 20 mM Tris-Cl, pH 7.5. Cells were lysed in SDS loading dye under non-reducing conditions 514 
(without β-Mercaptoethanol) and separated on 10% SDS-PAGE and immunoblotted for detection of 515 
indicated proteins. For endogenous immunoprecipitation, HEK293 cells were lysed in lysis buffer 516 
(same as above) and centrifuged at 100,000 x g for 1 hour before preclearing with protein G-517 
Sepharose. Lysates were incubated with 2 µg of anti-STING antibody (Cell Signaling Technologies) 518 
overnight and subsequently with protein G-Sepharose for 2 hours. For immunoprecipitation of STING 519 
SAVI mutants with endogenous STIM1, HEK293T stably expressing FLAG-tagged human STINGWT, 520 
STINGV147M, STINGN154S or STINGV155M cDNAs were lysed in lysis buffer (same as above), centrifuged 521 
at 100,000 x g for 1 hour, pre-cleared and incubated with anti-FLAG antibody-conjugated resin 522 
overnight in lysis buffer containing 0.1% Igepal CA-630 and processed as described above. PBMCs 523 
were lysed in NP40 Lysis Buffer (VWR Life Science) containing cOmplete Protease Inhibitor Cocktail 524 
(Sigma-Aldrich) and centrifuged to remove debris. 20 µg of total protein from healthy control or patient 525 
samples was separated on a 4-12% Bis-Tris Plus Gel (ThermoFisher), transferred to polyvinylidene 526 
difluoride (PVDF) membrane and subsequently analyzed by immunoblotting with relevant antibodies.  527 
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Purification of recombinant proteins from E. coli. Full-length and fragments (a.a. 1-249, 250-400, 528 
324-448, 400-600, and 600-685) of STIM1 were subcloned into pGEX4T-1 plasmid. GST fusion 529 
protein expressing transformants were grown in liquid cultures and induced with isopropyl-1-thio-ȕ-D-530 
galactopyranoside (IPTG, 0.2 mM) at 18°C overnight. Subsequently, cells were harvested and 531 
resuspended in lysis buffer (50 mM NaH2PO4, 500 mM NaCl, 10% glycerol, pH 8.0) containing 532 
protease inhibitors and 0.5% Triton X-100. Lysates were sonicated, centrifuged to remove debris and 533 
incubated with glutathione sepharose 4B beads for 2 hrs. After washing 8 times with lysis buffer, the 534 
beads were stored in lysis buffer without Triton X-100 at -20!C. 535 
GST pulldown analysis. cDNA encoding full-length and fragments of STING-FLAG was transfected 536 
into HEK293T cells. Transfected cells (2 x 107) were lysed in lysis buffer (20 mM Tris-Cl, 2 mM EDTA, 537 
135 mM NaCl, 10% (vol/vol) glycerol, 0.5% Igepal CA-630, protease inhibitor mixture, pH 7.5) and 538 
centrifuged at 100,000 x g for 1 hour before preclearing with protein G-Sepharose. Lysates were 539 
incubated with 20 µg of GST or GST-tagged fragments of STIM1 for 18 hours in binding buffer (0.5% 540 
Igepal CA-630, 20 mM Tris-HCl, 100 mM NaCl, 2 mM EDTA, 10% glycerol, protease inhibitors, pH 541 
7.5). Pulldown samples were washed five times with lysis buffer and analyzed by immunoblotting for 542 
indicated proteins. 543 
HSV infection in mice. Age and gender-matched control (Stim1fl/fl or Orai1fl/fl), Stim1fl/flLyz2-cre or 544 
Orai1fl/flLyz2-cre mice were intravenously injected with 1 x 107 pfu of HSV-1 17+ strain. The viability of 545 
the infected mice was monitored for 10 days. Mouse serum was collected at indicated times after 546 
infection for measurement of serum cytokine by ELISA.  547 
Statistical analysis. Statistical analysis was performed using the Origin2018b software (OriginLab, 548 
Northampton, MA, USA). Data are presented as meanௗ±ௗs.e.m. For all dataset, normality and 549 
homogeneity of variance were evaluated by Shapiro-Wilk test and Levene test respectively, to ensure 550 
that the assumptions inherent to parametric significance testing were not violated. Statistical 551 
significance to compare two quantitative groups was evaluated using two-tailed/unpaired t-test. When 552 
multiple groups and/or multiple condition comparisons were necessary, one-way or two-way ANOVA 553 
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was performed followed by a Tukey HSD post-hoc test. Statistical comparison of multiple counts in 554 
contingency tables was performed using Chi-square test followed by pairwise analysis of differences 555 
as post-hoc test. A critical value for significance of Pௗ<ௗ0.05 was used throughout the study, and 556 
statistical thresholds of 0.05, 0.005 as well as 0.0005 are indicated in the figures by asterisks (see 557 
legends for details). 558 
 559 
Data availability 560 
The data that support the findings of this study are available from the corresponding authors upon 561 
request. The manuscript describing clinical phenotype of STIM1 patient is available from OSR 562 
Preprints (https://doi.org/10.31219/osf.io/4duxt). 563 
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Figure Legends  720 
Figure 1. STIM1 deficiency spontaneously induces type I IFN response in murine and human 721 
cells. a, Representative immunoblot showing expression of STIM1 in wild type (WT) and Stim1Ð/Ð 722 
MEFs (left). qPCR analysis of indicated cytokines and ISGs in unstimulated indicated MEFs (right). 723 
qPCR data show pooled technical replicates from two independent experiments (Ifnb1 and Il6) and 724 
one representative triplicate from two independent experiments (other genes). b, Levels of secreted 725 
IFNǦβ from culture supernatants of unstimulated WT or Stim1Ð/Ð MEFs. c, Representative traces 726 
showing averaged SOCE from WT (31 cells), Orai1Ð/Ð (30 cells) and Stim1Ð/Ð (29 cells) MEFs after 727 
passive depletion of intracellular Ca2+ stores with 1 µM thapsigargin (TG) in the presence of external 728 
solution containing 20 mM Ca2+ (left). Bar graph (middle) shows averaged baseline subtracted SOCE 729 
(± s.e.m.) from four independent experiments. right: qPCR analysis of Ifnb1 mRNA in indicated MEFs. 730 
d, Representative immunoblot showing expression of STIM1 in BMDMs (left). qPCR analysis of Ifnb1 731 
and Il6 mRNA in unstimulated WT and Stim1Ð/Ð BMDMs (right). e, Immunoblot showing expression of 732 
STIM1 in wild type (WT) and STIM1Ð/Ð THP1 cells generated using two independent sgRNAs (sg#2) 733 
and 3 (sg#3). qPCR analysis of IFNB1 and IL6 mRNA in unstimulated WT, STIM1Ð/Ð THP1 cells and 734 
those reconstituted for expression of STIM1 (right two panels).  f, Secreted IFNǦβ levels from culture 735 
supernatants of untreated or PMA-differentiated WT or STIM1Ð/Ð THP1 cells. Data show 736 
representative triplicate from two independent experiments (panels b, e and f) or pooled technical 737 
replicates from two (c) or three (d) independent experiments. All immunoblot data (panels a, d and e) 738 
are representative of three independent experiments with similar results. Data are shown as mean ± 739 
s.e.m. *p < 0.005, and **p < 0.0005 (unpaired/two-tailed t test – a, b, d; One-way ANOVA – c; and 740 
Two-way ANOVA – e).  741 
 742 
Figure 2. STING-TBK1-IRF3 pathway links loss of STIM1 expression to Ifnb1 transcription. a, 743 
qPCR analysis of Ifnb1 mRNA in indicated MEFs under resting conditions or after stimulation with 744 
2’,3’-cGAMP for 2 or 4 h (left). Numbers on top indicate average fold change relative to WT MEFs. 745 
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Secreted IFN-β levels from culture supernatants of indicated MEFs after stimulation with 2’,3’-cGAMP 746 
(right). Data show pooled technical replicates from two independent experiments (qPCR) or one 747 
representative triplicate from two independent experiments (ELISA) with similar results. b, qPCR 748 
analysis of Ifnb1 transcripts in indicated MEFs transfected with interferon stimulatory DNA (ISD), 749 
poly(dA:dT) or poly (I:C) for indicated time (left). qPCR analysis of IFNB1 mRNA from untreated or 750 
indicated nucleic acid-transfected THP1 cells. c, Representative confocal images showing localization 751 
of GFP-IRF3 in indicated MEFs. Bar graph below depicts quantification from indicated number of 752 
cells. Scale bars, 5 ȝm. d, Representative immunoblot for detection of IRF3 under non-reducing 753 
conditions in DSP-crosslinked indicated MEFs, (left). Bar graph (right) shows densitometry analysis of 754 
IRF3 ratio (dimer/monomer) from three independent experiments. e, Representative immunoblots 755 
showing expression of phospho-TBK1 (P-TBK1), total TBK1, and ߚ-actin from indicated cells. 756 
Numbers below indicate normalized fold change in ratio of P-TBK1/total TBK1. f, Representative 757 
immunoblots showing expression of STIM1 and STING in WT, Stim1Ð/Ð, or Stim1Ð/Ð and Tmem173Ð/Ð 758 
double knock out (DKO) MEFs (left). Expression of Ifnb1 and Il6 transcripts in indicated MEFs under 759 
resting conditions (left two panels) or 4 h after stimulation with 2’,3’-cGAMP (right two panels). g, 760 
Secreted IFN-β levels from culture supernatants of indicated MEFs after stimulation with indicated 761 
nucleic acids. h, Representative immunoblots showing expression of STIM1 and STING in WT, 762 
STIM1Ð/Ð, TMEM173Ð/Ð or STIM1Ð/Ð and TMEM173Ð/Ð double knock out (DKO) THP1 cells (left). 763 
Representative traces of averaged SOCE from WT (33 cells), STIM1Ð/Ð, (30 cells), TMEM173Ð/Ð (31 764 
cells) and DKO (31 cells) THP1 cells after passive depletion of intracellular Ca2+ stores with 1 µM 765 
thapsigargin (TG) in the presence of external solution containing 2 mM Ca2+ (middle). Bar graph 766 
shows averaged baseline subtracted SOCE (± s.e.m.) from three independent experiments. Right 767 
panels show qPCR analysis of IFNB1 or IL6 mRNA in indicated THP1 cells. Data show representative 768 
triplicates from two independent experiments with similar results (b, d, f, g and h) unless indicated. All 769 
immunoblots are representative of at least three independent experiments with similar results. Data 770 
are shown as mean ± s.e.m. *p < 0.05, **p < 0.005, ***p < 0.0005 [Two-way ANOVA – a (left panel); 771 
unpaired/two-tailed t test – a (right panel), b; Chi-square test – c; and One-way ANOVA – d, f, g, h].   772 
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Figure 3. STIM1 deficiency causes enhanced type I IFN response in patient cells. a, 773 
Representative immunoblot showing expression of STIM1 in WT, Stim1Ð/Ð MEFs or those expressing 774 
either WT STIM1 (+STIM1) or STIM1E136X (+E136X) mutant. b, qPCR analysis of Ifnb1 and Il6 mRNA 775 
in indicated MEFs under resting conditions or 2 h after stimulation with 2’,3’-cGAMP. Data show 776 
representative triplicate from two independent experiments. c, Representative immunoblot showing 777 
expression of STIM1 and GAPDH in PBMCs isolated from a healthy control (HC) and patient (Pat.). d, 778 
Levels of indicated cytokines in serum samples from healthy controls (three independent donors) and 779 
STIM1-deficient patient. Data show one representative triplicate from two independent experiments 780 
(n=9 for three HCs). e, Taqman qPCR analysis of indicated ISGs from peripheral blood mononuclear 781 
cells (PBMCs, top) or purified monocytes (below) from two independent healthy controls and STIM1-782 
deficient patient. Patient data (normalized to those of healthy controls) are derived from two 783 
independent experiments performed in duplicates. Data are shown as mean ± s.e.m. *p < 0.05, **p < 784 
0.005, ***p < 0.0005 (One-way ANOVA – b; and unpaired/two-tailed t test – d, e).  785 
 786 
Figure 4. STIM1 interacts with STING for its retention in the endoplasmic reticulum. a, 787 
Representative confocal microscopy image of STING-GFP and STIM1 in a MEF cell. Scale bar, 5 µm, 788 
Inset – 1 µm. Pearson’s r = 0.67 ± 0.08 from 9 cells. b, FLAG-immunoprecipitates (IP) from lysates of 789 
HEK293T cells overexpressing FLAG-tagged STING and His-tagged STIM1 were immunoblotted for 790 
detection of STIM1. Arrow, monomeric STING or STIM1; *, STING multimers. c, Immunoprecipitates 791 
of endogenous STING from HEK293 cells were immunoblotted for detection of indicated proteins. d, 792 
FLAG-immunoprecipitates (IP) from lysates of HEK293T cells expressing FLAG-tagged STING and 793 
His-tagged STIM1 with or without treatment with thapsigargin (1 µM, 10 min; left) or 2’, 3’-cGAMP (1 794 
µM, 30 min and further incubation in media for 1 h) were immunoblotted for detection of the indicated 795 
proteins. Bar graphs show densitometry analysis of normalized fold changes (mean ± s.e.m.) in 796 
STIM1 and STING band intensity from three (left) and four (right) independent experiments. e, 797 
Schematic showing domain structure of STING and STIM1 as indicated in the text. Amino acid 798 
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residues of STING and STIM1 fragments used in this study are indicated. f, Left – FLAG-799 
immunoprecipitates (IP) from lysates of HEK293T cells expressing FLAG-tagged full-length STING 800 
(FL), NTD (a.a. 1-140), and CTD (a.a. 140-379) were immunoblotted for detection of STIM1. Right – 801 
Purified recombinant GST-fused indicated fragments of STIM1 incubated with lysates of HEK293T 802 
cells expressing FLAG-tagged, FL, NTD or CTD of STING were immunoblotted with anti-FLAG 803 
antibody. Immunoblots in panels b, c, and f are representative of four independent experiments. *p < 804 
0.005 (unpaired/two-tailed t test - d).  805 
 806 
Figure 5. STIM1 inhibits STING trafficking to the ER-Golgi intermediate compartment. a, 807 
Representative confocal microscopy images of WT or Stim1Ð/Ð MEFs stably expressing STING-GFP 808 
under resting conditions (top two panels) or 4 h after HSV-1 infection (bottom 3 panels) and stained 809 
for endogenous p58 (ERGIC). Scale bars, 10 µm. Bar graph shows quantification of indicated number 810 
of cells showing STING translocation to the ERGIC under resting conditions or after infection with 811 
HSV-1 for indicated times. Data are derived from two independent experiments. b, Representative live 812 
cell epifluorescence images of WT (top) or Stim1Ð/Ð (bottom) MEFs after treatment with 1 µM 2’, 3’-813 
cGAMP for the indicated times showing translocation of STING-GFP into the ERGIC (left). Line graph 814 
on the right shows normalized rate of translocation of STING in WT (9 cells) and Stim1Ð/Ð (11 cells) 815 
MEFs from two independent experiments. Scale bar, 10 µm. c, Reporter assays for Ifnb1 promoter 816 
activity in HEK293T cells transfected with STING and increasing amounts of full length STIM1 or its 817 
indicated fragments, 6 hours after stimulation with 2’, 3’ cGAMP (top) or poly(I:C) (below). Data show 818 
representative triplicate from two independent experiments. *p < 0.005, **p < 0.0005 Chi square test 819 
(a) and one-way ANOVA (c); N.S. – not significant. 820 
 821 
Figure 6. Ablation of STIM1 enhances host defense towards DNA viruses and HIV by priming 822 
type I IFN responses. a, qPCR analysis of Ifnb1 and GFP transcripts in uninfected or HSV-1-GFP-823 
infected (MOI 0.1, 24 h) WT or Stim1Ð/Ð MEFs. Data show pooled technical replicates from two 824 
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independent experiments. b, qPCR analysis of GFP and indicated viral mRNAs in MHV-68-GFP-825 
infected (MOI 0.2, 24 h) WT or Stim1Ð/Ð MEFs. Data show pooled technical replicates from three 826 
independent experiments. c, Representative immunoblots showing expression of phospho-IRF3 (P-827 
IRF3), total IRF3, and ߚ-actin from untreated or HSV-1-infected (MOI 5.0) WT or Stim1Ð/Ð MEFs for 828 
indicated time points.  d, qPCR analysis of Ifnb1 and Il6 mRNA in untreated or HSV-1-GFP-infected 829 
(indicated MOI, 24 h) WT or Stim1Ð/Ð  BMDMs. Data shows representative triplicate from two 830 
independent experiments. e, Top two panels show representative GFP images in HSV-1-GFP-831 
infected (MOI 10, 24 h) WT, (left) and STIM1Ð/Ð (right) THP-1 cells. Below: qPCR analysis of IFNB1 832 
and GFP transcripts from the same cells. Scale bars, 10 µm. Data shows representative triplicate from 833 
two independent experiments. f, Representative flow plots showing frequency of HIV-GFP-infected 834 
WT (left) or two different STIM1Ð/Ð (right two panels) THP1 cell lines (MOI 2.0, 24 h). Bar graph shows 835 
averaged frequency of HIV-GFP-positive indicated THP1 cell lines in the presence or absence of HIV 836 
reverse transcriptase inhibitor azidothymidine (AZT, 5 µM) from four independent experiments. 837 
Immunoblots in panel c and epifluorescence images in panel e are representative of three and two 838 
independent experiments respectively. *p < 0.005 and **p < 0.0005 [Two-way ANOVA – a (left panel), 839 
d, e (right panel), f; unpaired/two-tailed t test – a (right panel), b; One-way ANOVA – e (left panel)]. 840 
 841 
Figure 7. STIM1 deficiency enhances host defense against HSV-1 infection in vivo. a, Kinetics of 842 
survival (top) and body weight changes (bottom) of indicated numbers of control (Stim1fl/fl) and STIM1-843 
deficient (Stim1fl/flLyz2-cre) mice (6-7-week old) after intravenous injection with HSV-1 (1 x 107 PFU 844 
per mouse). b, Kinetics of survival (top) and body weight changes (bottom) of indicated numbers of 845 
control (Orai1fl/fl) and Orai1-deficient (Orai1fl/flLyz2-cre) mice after intravenous injection with HSV-1 (1 846 
x 107 PFU per mouse). Mice that lost >20% body weight were euthanized. c, Virus load in control 847 
(Stim1fl/fl) and STIM1-deficient (Stim1fl/flLyz2-cre) mouse brains 3 days after intravenous injection with 848 
HSV-1. d, ELISA analyses of the indicated cytokines from the sera of control (Stim1fl/fl) and Stim1-849 
deficient (Stim1fl/fl Lyz2-cre) mice after intravenous injection with HSV-1 for indicated times. Data in 850 
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panels a and b are pooled from two independent experiments. Panels c and d show mean +/- s.e.m. 851 
from indicated number of animals (each symbol represents data from individual animal). *p < 0.05, **p 852 
< 0.005, ***p < 0.0005 (unpaired/two-tailed t test).  853 
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SUPPLEMENTAL INFORMATION 1 
Supplementary Table 2 
Supplementary Table 1. List of primers and sgRNAs used in this study 3 
 4 
Gene name Forward Primer Reverse Primer Comments 
STIM1_pLentiguide_sg1 
 
CACCGCATCATCGTCCATCAGT
TTG 
 
AAACCAAACTGATGGACGATGAT
GC 
sgRNA targeting 
human STIM1 
STIM1_ pLentiguide_sg2 
CACCGCCGTAACATCCACAAA
CTGA 
AAACTCAGTTTGTGGATGTTACG
GC 
sgRNA targeting 
human STIM1 
STIM1_ pLentiguide_sg3 
CACCGTGAGGATAAGCTCATC
AGCG 
AAACCGCTGATGAGCTTATCCTC
AC 
sgRNA targeting 
human STIM1 
STIM2_pLentiguide_sg1 
CACCGAGAAGAAGACAGATTTA
GTC 
AAACGACTAAATCTGTCTTCTTCT
C 
sgRNA targeting 
human STIM2 
STIM2_ pLentiguide_sg2 
CACCGAGATGGTGGAATTGAA
GTAG 
AAACCTACTTCAATTCCACCATCT
C 
sgRNA targeting 
human STIM2 
STIM2_ pLentiguide_sg3 
CACCGAGATAAACATATAACGA
TTG 
AAACCAATCGTTATATGTTTATCT
C 
sgRNA targeting 
human STIM2 
TMEM173_pLentiguide_sg 
CACCGAATATGACCATGCCAG
CCCA 
AAACTGGGCTGGCATGGTCATAT
TC 
sgRNA targeting 
human STING 
Ifnb 
AACCTCACCTACAGGGCGGAC
TTCA 
TCCCACGTCAATCTTTCCTCTTGC
TTT 
sgRNA targeting 
human STIM1 
2 
 
Mx1 GACCATAGGGGTCTTGACCAA AGACTTGCTCTTTCTGAAAAGCC qPCR primers 
Mx2 
GAGGCTCTTCAGAATGAGCAA
A CTCTGCGGTCAGTCTCTCT qPCR primers 
Irf7 GAGACTGGCTATTGGGGGAG GACCGAAATGCTTCCAGGG qPCR primers 
Ccl2 
TTAAAAACCTGGATCGGAACCA
A 
GCATTAGCTTCAGATTTACGGGT qPCR primers 
Il6 ACAACCACGGCCTTCCCTACTT CACGATTTCCCAGAGAACATGT qPCR primers 
36b4 
AGATTCGGGATATGCTGTTGG
C 
TCGGGTCCTAGACCAGTGTTC qPCR primers 
IFNB AGGACAGGATGAACTTTGAC TGATAGACATTAGCCAGGAG qPCR primers 
IL6 CCAGCTATGAACTCCTTCTC GCTTGTTCCTCACATCTCTC qPCR primers 
36B4 AGATGCAGCAGATCCGCAT GTTCTTGCCCATCAGCACC qPCR primers 
MO70_TMEM173 
GCG CTC GAG ATG CCC CAC 
TCC AGC CTG 
GCG GAA TTC AGA GAA ATC 
CGT GCG GAG 
Sub-cloned in 
MO70 using XhoI 
and EcoRI sites 
MO70_TMEM173_TM 
CCG CTC GAG ATG CCC CAC 
TCC AGC CTG 
CGG AAT TCG TTG AAA TTC CCT 
TTT TC 
Sub-cloned in 
MO70 using XhoI 
and EcoRI sites 
MO70_TMEM173_CTD 
CCG CTC GAG ATG GAA AAA 
GGG AAT TTC AAC 
CGG AAT TCA GAG AAA TCC 
GTG CGG AG 
Sub-cloned in 
MO70 using XhoI 
and EcoRI sites 
MO70_TMEM173_V147L 
GAG ATC TCT GCA TTG TGT 
GAA AAA G 
CTT TTT CAC ACA ATG CAG AGA 
TCT C Site directed 
3 
 
mutagenesis  
MO70_ TMEM173_N154S 
AAG GGA ATT TCA GCG TGG 
CCC ATG G 
CCA TGG GCC ACG CTG AAA 
TTC CCT T 
Site directed 
mutagenesis 
MO70_ TMEM173_V155M 
GGG AAT TTC AAC ATG GCC 
CAT GGG C 
GCC CAT GGG CCA TGT TGA 
AAT TCC C 
Site directed 
mutagenesis 
GFP  
AAGCTGACCCTGAAGTTCATCT
GC 
CTTGTAGTTGCCGTCGTCCTTGA
A 
qPCR primers 
MHV68_ORF29 
CCA CCA AAA ACA TGT GTC 
CT 
TTG CTG GAA GTG CTT CCT TCT qPCR primers 
MHV68_ORF57 GACCAAATGATGGAAGGAC GCAGAGGAGAGTTGTGGAC qPCR primers 
pEGFPC1_Tmem173 
AGA TCT CGA GCT ATG CCA 
TAC TCC AAC CTG CAT 
GCG GAA TTC TCA GAT GAG 
GTC AGT GCG GAG 
Murine STING in 
pEGFPC1 vector 
using XhoI and 
EcoRI sites 
Interferon Stimulatory DNA 
(ISD) 
TACAGATCTACTAGTGATCTAT
GACTGATCTGTACATGATCTAC
A 
TGTAGATCATGTACAGATCAGTC
ATAGATCACTAGTAGATCTGTA 
 
Orai1_Flox_Genotyping 
AGGCGGCCTATAATTCCAGCTT
CA 
AGGTGGATGTTGCTGAGAGACCA
A 
WT band 222 
bps, Flox band – 
378 bps 
Orai1_cKO_Genotyping 
GATTGACAGTGGCAGTGTTCC
CAA 
TCCTGTTTAAGCTAACAAGGAGC
GGC 
220 bps KO band 
 5 
 6 
4 
 
 7 
Supplementary Figure Legends: 8 
Supplementary Figure 1. Sequencing data for STIM1-/- THP1 clones generated using CRISPR-9 
Cas9 system. Top - alignment of sequences within exon 2 and 3 of human STIM1 gene with the ones 10 
from individual clones (sg# 2 and sg#3). The sgRNA sequences are highlighted in red. Below – 11 
Sequencing results of individual clones. Boxed areas mark the indel sites. Clone sg#2 shows insertion 12 
of 3 nucleotides and deletion of 2 nucleotides whereas sg#3 shows deletion of 5 nucleotides.  13 
Supplementary Figure 2. Lack of spontaneous induction of the type I IFN response in STIM2-/- 14 
THP1 cells. Left – Immunoblot showing expression of STIM2 in control or STIM2-/- THP1 cells 15 
generated using two independent sgRNAs (sg#1 and sg#2). Loss of STIM2 does not alter expression 16 
of STIM1 or STING in these cells. Right - qPCR analysis of IFNB1 transcripts in unstimulated control 17 
and STIM2-/- THP1 cells. N.S. – not significant. Data shows representative triplicate from two 18 
independent experiments. 19 
Supplementary Figure 3. STIM1 deficiency induces dimerization of STING. a, Immunoblots from 20 
two representative experiments (Exp #1 and #2) showing endogenous STING in control, Stim1-/- and 21 
Orai1-/- MEFs under non-reducing SDS PAGE conditions. * indicates the position of monomeric and 22 
dimeric STING. b, Lysates from untreated or DSP-treated (0.125, 0.25, 0.5, 1.0 and 2.0 mM, 1 hour 23 
on ice) control or STIM1-/- HEK293T cells expressing STING-FLAG were immunoblotted for detection 24 
of STING under non-reducing conditions (left). Bar graph shows averaged ratio of STING 25 
(dimer/monomer) from three independent experiments (right). *p < 0.05 (unpaired/two-tailed t test). 26 
Supplementary Figure 4. Overexpression or deletion of STING affects SOCE and STIM1 27 
translocation kinetics. a, Representative traces of averaged SOCE from HEK293T cells expressing 28 
empty vector (24 cells) or that encoding STING (27 cells) after passive depletion of intracellular Ca2+ 29 
stores with 1 µM thapsigargin in the presence of external solution containing 2 mM Ca2+ as indicated. 30 
b, Representative traces of averaged SOCE from Jurkat T cells expressing empty vector (54 cells) or 31 
that encoding STING (49 cells). c, Representative traces of averaged SOCE from Jurkat T cells 32 
expressing empty vector (49 cells) or that encoding STING (53 cells) after stimulation with 10 µg/ml of 33 
Į-CD3 antibody or 0.5 µM ionomycin in the presence of external solution containing 2 mM Ca2+ as 34 
indicated. d, Representative epifluorescence (left) and total internal reflection fluorescence (TIRF, 35 
right) images of WT or Sting-/- MEFs stably expressing STIM1-YFP under resting conditions or 10 36 
mins after depletion of intracellular Ca2+ stores using 1 µM thapsigargin (TG). Scale bar, 10 µm. Line 37 
graph on the right shows mean normalized fluorescence intensity ± s.e.m. of STIM1-YFP in WT (6 38 
cells) and Tmem173-/- MEFs (9 cells) from two independent experiments. e, Left – Immunoblot 39 
showing expression of indicated proteins in control and TMEM173-/- Jurkat T cells. Right panels show 40 
representative traces of averaged SOCE from control (54 cells) and TMEM173-/- (58 cells) Jurkat T 41 
5 
 
cells. f, Representative traces of averaged SOCE from control (66 cells) and TMEM173-/- (60 cells) 42 
Jurkat T cells after stimulation with anti-CD3 antibody (2 µg/ml) in the presence of external solution 43 
containing 2 mM Ca2+ as indicated. Bar graphs in panels a-c, e and f show averaged baseline 44 
subtracted peak SOCE (± s.e.m.) from three independent experiments. *p<0.05, **p < 0.005, 45 
***p<0.0005 (unpaired/two-tailed t test). 46 
Supplementary Figure 5. Functional Interaction of constitutively active STING mutants with 47 
STIM1. a, FLAG-immunoprecipitates (IP) from lysates of HEK293T cells stably expressing FLAG-48 
tagged WT or indicated mutants of STING were immunoblotted for detection of endogenous STIM1 49 
proteins (left). Bar graph (right) shows densitometry analysis of normalized (relative to WT STING) 50 
fold change in STIM1 band intensity from seven independent experiments. b, Reporter assay for Ifnb1 51 
promoter activity in HEK293T cells transfected with WT or mutant STING proteins and full-length 52 
STIM1 or its N-terminal fragment (a.a. 1-249) for 24 hours (right). Data shows representative triplicate 53 
from two independent experiments. c, Representative confocal microscopy images of MEFs stably 54 
expressing WT STING-GFP or indicated SAVI mutants without or with STIM1. Cells were either 55 
stained for endogenous p58 (ERGIC marker, left three panels) or STIM1 (+ STIM1, right three 56 
panels). Scale bar, 10 µm. Images are representative of 25-30 cells for each condition. *p < 0.05, **p 57 
< 0.005, and ***p < 0.0005 (unpaired/two-tailed t test – a; One-way ANOVA - b). 58 
Supplementary Figure 6. STIM1 plays a Ca2+-independent role in the anti-viral immune 59 
response. a, qPCR analysis of GFP (left) and Ifnb1 (right) transcripts in WT, Orai1-/- or Stim1-/- MEFs 60 
uninfected or HSV-1-GFP-infected with indicated MOI. b, qPCR analysis of GFP (left) transcripts in 61 
HSV-GFP-infected (MOI 0.5, 24 hours) WT or Stim1-/- MEFs in the presence or absence of indicated 62 
amounts of tofacitinib. Cells were preincubated with the inhibitor for 30 mins prior to infection. Data 63 
shows representative triplicate from two independent experiments. Data are shown as mean ± s.e.m. 64 
*p < 0.05, **p < 0.005, and ***p < 0.0005 (Two-way ANOVA – a; unpaired/two-tailed t test -b). 65 
Supplementary Figure 7. Generation of conditionally targeted Orai1-deficient mice. a, 66 
Schematic showing the architecture of mouse Orai1 gene. Exon 2 of the Orai1 gene was targeted. By 67 
homologous recombination, Orai1+/fl mice with loxP sites (red arrowheads) flanking exon 2 were 68 
generated. Germ-line transmission of flox alleles was validated by genotyping PCR (lower panel). The 69 
location of the primer pair is indicated as green (5’ and 3’) arrows. A 378 bp-band is derived from the 70 
flox allele while a 200-bp band denotes the WT allele. b, qPCR analysis of Orai1 transcripts in control 71 
(Orai1fl/fl) or Orai1-/- BMDMs 7 days after differentiation. Data shows representative triplicate (mean ± 72 
s.e.m., unpaired/two-tailed t test) from two independent experiments c, Representative traces of 73 
averaged SOCE from Orai1fl/fl (36 cells) and Orai1-/- (41 cells) BMDMs 7 days after differentiation and 74 
after passive depletion of intracellular Ca2+ stores with 1 µM thapsigargin in the presence of external 75 
solution containing 2 mM Ca2+ as indicated. Data are representative of three independent 76 
experiments.  77 
